Carolyn A. Felix, MD, is an attending physician at the Cancer Center at Children's Hospital of Philadelphia, with an expertise in treating leukemia in children.
Areas of Expertise:
Leukemia as a complication of anticancer treatment, Leukemia in infants, Molecular pathogenesis of childhood leukemia Locations:Main Hospital Appointments and Referrals: 1-800-TRY-CHOP(1-800-879-2467)
Education and Training
MD - Boston University School of Medicine, Boston, MA
Pediatrics - Children's Hospital of Pittsburgh, PA
Pediatrics - Children's Hospital of Pittsburgh, PA
Medical Staff Fellow - National Cancer Institute, Pediatric Branch, NIH, Bethesda, MD
Biotechnology Fellow - Pediatric Branch, National Cancer Institute, Bethesda, MD
Hematology – American Board of Internal MedicinePediatrics – American Board of Pediatrics
Titles and Academic Titles
Professor of Pediatrics, Perelman School of Medicine at the University of Pennsylvania
Robinson BW, Kairalla JA, Devidas M, Carroll AJ, Harvey RC, Heerema NA, Willman CL, Ball AR, Woods EC, Ballantyne NC, Urtishak KA, Behm FG, Reaman GH, Hilden JM, Camitta BM, Winick NJ, Pullen J, Carroll WL, Hunger SP, Dreyer ZE, Felix CA. KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. Haematologica. 2023 Mar 2. Epub 2023/03/03. doi:10.3324/haematol.2022.281552. PMID 36861410.
Felix, CA, Slater, DJ, Davenport, JW, Yu, X, Gregory, BD, Li, MM, Rappaport, EF, Cheung, NV. KMT2A-MAML2 Rearrangement Emerged and Regressed During Neuroblastoma Therapy without Leukemia after 12.8-Year Follow-Up. Pediatr Blood Cancer. Jan 2022; 69(1): e29344. http://dx.doi.org/10.1002/pbc.29344.
Germano, G, Porazzi, P, Felix, CA. Leukemia-Associated Transcription Factor Mllt3 Is Important for Primitive Erythroid Development in Zebrafish Embryogenesis. Dev Dyn (Apr 16 2022). http://dx.doi.org/10.1002/dvdy.477.
Chen, C, Yu, W, Alikarami, F, Qiu, Q, Chen, CH, Flournoy, J, Gao, P, Uzun, Y, Fang, L, Davenport, JW, Hu, Y, Zhu, Q, Wang, K, Libbrecht, C, Felmeister, A, Rozich, I, Ding, YY, Hunger, SP, Felix, CA, Wu, H, Brown, PA, Guest, EM, Barrett, DM, Bernt, KM, Tan, K. Single-cell multiomics reveals increased plasticity, resistant populations and stem-cell-like blasts in KMT2A-rearranged leukemia. Blood. 2021 Dec 5. pii: 482898. doi: 10.1182/blood.2021013442. PMID: 34864916
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, Teachey DT, Tasian SK, Moore JS, Seif AE, Jin S, Barrett JS, Robinson BW, Chen IL, Harvey RC, Carroll MP, Carroll AJ, Heerema NA, Devidas M, Dreyer ZE, Hilden JM, Hunger SP, Willman CL, Borden KLB, Felix CA. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019;38(13):2241-2262.Epub 2018 Nov 26. PMID: 30478448.
Yu, X., Davenport, J.W., Urtishak, K.A. Carillo, M.L., Gosai, S.J., Kolaris, C.P., Byl, J.A.W., Rappaport, E.F., Osheroff, N., Gregory, B.D.*, Felix, C.A.* (*Co-corresponding). Genome-Wide TOP2A DNA Cleavage is Biased Towards Translocated and Highly Transcribed Loci. Genome Res. 27 (7) 1238-1249; 2017; Accession Number 28385713; doi 10.1101/gr.211615.116; PMC5495075.
Urtishak, K. A., Robinson, B. W., Rappaport, E. F., Sarezky, M. D., Biegel, J. A., Nichols, K. E., Wilmoth, D. M., Wang, L. S., Stern, J. W., Felix, C. A. Unique Familial MLL(KMT2A)-Rearranged Precursor B Cell Infant Acute Lymphoblastic Leukemia (ALL) in Non-twin Siblings. Pediatr Blood Cancer [Epub 2016 March 21. doi: 10.1002/pbc.25957] Accession Number 26999444.
Awards and Honors
2012, Joshua Kahan Endowed Chair in Pediatric Leukemia
2007, America's Top Doctors For Cancer
2006, Eagles Fly for Leukemia Award for Excellence in Treatment of Pediatric Cancer Patients
2006, Association of American Physicians (Elected Member)
2005-2006, 2009-2012, Philadelphia Magazine Top Doctors
2003, Society for Pediatric Research (Elected Member)
2001, Stohlman Scholar Award, Leukemia & Lymphoma Society
2000, Honorary Master of Arts Degree, University of Pennsylvania
2000, Eastern Pennsylvania Chapter Leukemia & Lymphoma Society Distinguished Leadership Award
1999, Klaus and Mary Hummeler Endowed Research Prize, The Children's Hospital of Philadelphia
1999, Eastern Pennsylvania Chapter Leukemia Society of America Distinguished Leadership Award
1992, American Society of Clinical Oncology Young Investigator Award
1991, American Association for Cancer Research Travel Award
1990, American Society of Pediatric Hematology-Oncology Young Investigator Award
1988, American Society of Hematology Travel Award
1987, American Society of Clinical Oncology Young Investigator in Training Travel Award
1977, Alpha Sigma Nu
1977, Alpha Epsilon Delta
1976, Phi Beta Kappa-junior year induction
1977, Graduated summa cum laude - Boston College, Chestnut Hill, MA
2011-2014, Hearings List for the Faculty Grievance Commission
2004-present, Research Affinity Group (RAG) Council, Joseph Stokes, Jr. Research Institute
2003-present, Normal and Malignant Hematopoiesis Research Affinity Group Leader
1999-present, University of Pennsylvania School of Medicine Combined Degree Admissions/Advisory Committee
1998, Founding Member, Center for Cancer Pharmacology, University of Pennsylvania Cancer Center
Leadership and Memberships
Memberships in Professional Organizations
2006-present, Association of American Physicians
2003-present, Society for Pediatric Research
2000-present, Children’s Oncology Group
1999-present, American Association for the Advancement of Science
1994-present, American Society of Hematology
1992-present, American Society of Clinical Oncology
1991-present, American Association for Cancer Research
1988-present, American Society of Pediatric Hematology-Oncology
Major Teaching and Clinical Responsibilities at the University of Pennsylvania
2022, External Examiner for PhD Thesis Committee of Grace Egan, MD, FRCP, Laboratory of Aaron D. Schimmer, MD, PhD, FRCPC, The Hospital for Sick Children and Princess Margaret Cancer Centre, University of Toronto
Patient Experience Ratings
About the Patient Experience Rating System
The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments.
Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care.
The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.